Candel Therapeutics (CADL) Non-Current Assets (2020 - 2025)

Candel Therapeutics has disclosed Non-Current Assets across 6 years of filings, most recently posting $3.8 million for Q4 2025.

• Non-Current Assets for Q4 2025 came in at $3.8 million, up 24.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.4 million (down 13.53% YoY), and the FY2025 annual result was $3.8 million, up 24.3% from the prior year.
• Non-Current Assets came in at $3.8 million for Q4 2025 at Candel Therapeutics, up from $3.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $6.3 million in Q2 2021 to a low of $2.4 million in Q2 2025.
• The 5-year median for Non-Current Assets is $4.4 million (2023), against an average of $4.5 million.
• Across the five-year window, Non-Current Assets jumped 35.84% in 2021 and plunged 37.07% in 2025, its largest moves.
• Candel Therapeutics' Non-Current Assets stood at $4.3 million in 2021, then jumped by 34.88% to $5.7 million in 2022, then declined by 23.36% to $4.4 million in 2023, then slumped by 30.47% to $3.1 million in 2024, then gained by 24.3% to $3.8 million in 2025.
• The last three Non-Current Assets figures came in at $3.8 million (Q4 2025), $3.5 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.